<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Clin Invest</journal-id><journal-id journal-id-type="publisher-id">eci</journal-id><journal-title>European Journal of Clinical Investigation</journal-title><issn pub-type="ppub">0014-2972</issn><issn pub-type="epub">1365-2362</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18489398</article-id><article-id pub-id-type="pmc">2439595</article-id><article-id pub-id-type="doi">10.1111/j.1365-2362.2008.01949.x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group><subject>Cardiovascular Diseases</subject></subj-group></subj-group></article-categories><title-group><article-title>Study comparing the double kissing (DK) crush with classical crush for the treatment of coronary bifurcation lesions: the DKCRUSH-1 Bifurcation Study with drug-eluting stents</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>S L</given-names></name><xref ref-type="aff" rid="au1">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>J J</given-names></name><xref ref-type="aff" rid="au1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>F</given-names></name><xref ref-type="aff" rid="au1">*</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Y D</given-names></name><xref ref-type="aff" rid="au2">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>T</given-names></name><xref ref-type="aff" rid="au3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Kawajiri</surname><given-names>K</given-names></name><xref ref-type="aff" rid="au4">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><xref ref-type="aff" rid="au5">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Kwan</surname><given-names>T W</given-names></name><xref ref-type="aff" rid="au6">**</xref></contrib><contrib contrib-type="author"><name><surname>Mintz</surname><given-names>G</given-names></name><xref ref-type="aff" rid="au7">&#x02020;&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>H C</given-names></name><xref ref-type="aff" rid="au8">&#x02021;&#x02021;</xref></contrib><aff id="au1"><label>*</label><institution>Nanjing First Hospital of Nanjing Medical University</institution><addr-line>Nanjing, China</addr-line></aff><aff id="au2"><label>&#x02020;</label><institution>Beijing Anzhen Hospital of Capital Medical University</institution><addr-line>Beijing, China</addr-line></aff><aff id="au3"><label>&#x02021;</label><institution>Krishina Heart Institute</institution><addr-line>Ahmedabad, India</addr-line></aff><aff id="au4"><label>&#x000a7;</label><institution>Tokushio Hospital</institution><addr-line>Osaka, Japan</addr-line></aff><aff id="au5"><label>&#x000b6;</label><institution>Queen Mary Hospital</institution><addr-line>Hong Kong, China</addr-line></aff><aff id="au6"><label>**</label><institution>Beth Israel Hospital</institution><addr-line>New York, USA</addr-line></aff><aff id="au7"><label>&#x02020;&#x02020;</label><institution>Cardiac Research Foundation, Columbia University</institution><addr-line>New York, USA</addr-line></aff><aff id="au8"><label>&#x02021;&#x02021;</label><institution>National University Hospital</institution><addr-line>Singapore</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr S. L. Chen, Cardiological Department, Nanjing First Hospital of Nanjing Medical University, Nanjing 210006, China. Tel./fax: 25-52208048, e-mail: <email>chmengx@126.com</email>; and Dr G. Mintz, Cardiac Research Foundation, Columbia University, New York, USA. e-mail: <email>gsm18439@aol.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2008</year></pub-date><volume>38</volume><issue>6</issue><fpage>361</fpage><lpage>371</lpage><history><date date-type="received"><day>29</day><month>9</month><year>2007</year></date><date date-type="accepted"><day>25</day><month>2</month><year>2008</year></date></history><copyright-statement>&#x000a9; 2008 The Authors. Journal Compilation &#x000a9; 2008 Blackwell Publishing</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>Classical crush has a lower rate of final kissing balloon inflation (FKBI) immediately after percutaneous coronary intervention (PCI). The double kissing (DK) crush technique has the potential to increase the FKBI rate, and no prospective studies on the comparison of classical with DK crush techniques have been reported.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Three hundred and eleven patients with true bifurcation lesions were randomly divided into classical (<italic>n</italic> = 156) and DK crush (<italic>n</italic> = 155) groups. Clinical and angiographic details at follow-up at 8 months were indexed. The primary end point was major adverse cardiac events (MACE) including myocardial infarction, cardiac death and target lesion revascularization (TLR) at 8 months.</p></sec><sec><title>Results</title><p>FKBI was 76% in the classical crush group and 100% in the DK group (<italic>P</italic> &#x0003c; 0&#x000b7;001). The incidence of stent thrombosis was 3&#x000b7;2% in the classical crush group (5&#x000b7;1% in without- and 1&#x000b7;7% in with-FKBI) and 1&#x000b7;3% in the DK crush group. Cumulative 8 month MACE was 24&#x000b7;4% in the classical crush group and 11&#x000b7;4% in the DK crush group (<italic>P</italic> = 0&#x000b7;02). The TLR-free survival rate was 75&#x000b7;4% in the classical crush group and 89&#x000b7;5% in the DK crush group (<italic>P</italic> = 0&#x000b7;002).</p></sec><sec><title>Conclusions</title><p>DK crush technique has the potential of increasing FKBI rate and reducing stent thrombosis, with a further reduction of TLR and cumulative MACE rate at 8 months.</p><p>Eur J Clin Invest 2008; 38 (6): 361&#x02013;371</p></sec></abstract><kwd-group><kwd>Coronary bifurcation lesions</kwd><kwd>DK crush</kwd><kwd>final kissing balloon inflation</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The percutaneous treatment of coronary bifurcation lesions is still limited by technical challenges and both restenosis and stent thrombosis even in the era of drug-eluting stents (DES) [<xref ref-type="bibr" rid="b1">1</xref>&#x02013;<xref ref-type="bibr" rid="b6">6</xref>]. During DES implantation, in order to improve ostial side branch coverage without compromising access to the side branch, the classical crush technique was developed [<xref ref-type="bibr" rid="b7">7</xref>]. Studies reported that final kissing balloon inflation (FKBI) after classical crush was mandatory to improve outcomes [<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref>]. In a previously published pilot study we modified the classical crush technique by developing &#x02018;double kissing (DK) double crush&#x02019; bifurcation stenting [<xref ref-type="bibr" rid="b10">10</xref>]. To study this technique in comparison to the classical crush technique, we organized a prospective, multicentre, randomized DKCRUSH-1 trial. In particular, we sought to determine the differences in rates of FKBIs as well as long term clinical outcomes.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Study population and randomization</title><p>From April 2005 to May 2006, 312 patients scheduled for percutaneous coronary intervention (PCI) of a true coronary bifurcation lesion (Lefevre Classification) [<xref ref-type="bibr" rid="b3">3</xref>] in eight centres from China, Singapore, India, Japan and the USA were randomized to classical crush versus DK crush techniques. Demographic and procedural characteristics were entered into a dedicated database. Randomization was performed in blocks for each participating centre with the ratio of 1 : 1 by computerized assignment. Patients were randomized before the wiring of any vessel. This project was approved by Ethical Committees in all participating centres, and all patients gave their formal written consent. All members had full access to the database and participated in the interpretation of data. A stent thrombosis rate of &#x02265; 5% in any group would necessitate premature termination of the trial.</p></sec><sec><title>Inclusion criteria</title><p>Inclusion criteria included main vessel &#x02265; 2&#x000b7;5 mm and side branch diameter &#x02265; 2&#x000b7;0 mm by visual estimation. Lesions in the main vessel had to be completely covered by two overlapped stents. Two or more bifurcation lesions were eligible as long as there was only one bifurcation lesion per vessel, and each lesion had to be treated by the strategy assigned at randomization. Patients with another single lesion in a different target vessel that could be covered by a single DES were also included.</p></sec><sec><title>Exclusion criteria</title><p>Patients were excluded if expected clinical survival was &#x0003c; 1 year or in the presence of concomitant liver dysfunction, plasma levels of creatinine &#x0003e; 200 Umol L<sup>&#x02212;1</sup>, a cerebrovascular event within 6 months, a history of previous coronary artery bypass grafting (CABG), or allergy to aspirin, clopidogrel and DES.</p></sec><sec><title>Implantation of DES</title><p>Paclitaxel-eluting stent (Boston Scientific, Natick, MA, USA) and sirolimus-eluting stents (Cardis, Johnson &#x00026; Johnson, Miami Lakes, FL, USA) were used. Deployment of additional DES to completely cover a dissection proximal or distal to a previous stent was allowed. Bare metal stents were not allowed. The procedural time was defined from &#x02018;guide wire in&#x02019; to &#x02018;guiding catheter out&#x02019;.</p><p>Classical and DK crush techniques have been described previously [<xref ref-type="bibr" rid="b7">7</xref>,<xref ref-type="bibr" rid="b10">10</xref>]. Briefly, the classical crush technique involves first delivering the side branch stent with 3&#x02013;5 mm protruding proximally into the main vessel, and then crushing the proximal portion of the side branch stent with the main vessel stent. The DK crush technique differes from the classical crush technique in that the part of the side branch stent protruding into the main vessel was first crushed with a balloon in the main vessel, then a first kissing balloon inflation was performed, next the main vessel was stented, and at the end a final kissing balloon inflation was performed.</p><p>Activated clotting time (ACT) &#x0003e; 280 s during the procedure was maintained using unfractionated heparin. Glycoprotein (GP) IIb/IIIa inhibitors were administered at the discretion of the operator. Clopidogrel (75 mg d<sup>&#x02212;1</sup>) was taken for at least 12 months and aspirin (100 mg d<sup>&#x02212;1</sup>) was recommended for life.</p></sec><sec><title>End points</title><p>The primary end point was major adverse cardiac events (MACE) at 8 months, including myocardial infarction, cardiac death, target lesion revascularization (TLR) by either PCI or CABG. Secondary end points included binary angiographic restenosis and late loss in both the main vessel and side branch after 8 months.</p><p>Myocardial infarction (MI) was defined as creatine kinase-MB (CK-MB) enzyme elevation &#x02265; 3 times the upper limit of the normal value, either with (Q wave MI) or without (non-Q wave MI), and new Q waves in at least two contiguous leads on electrocardiogram. TLR was defined as repeat revascularization with a diameter stenosis &#x02265; 50% within the stent or in the 5 mm distal or proximal segments adjacent to the stent. Target vessel revascularization (TVR) was defined as repeat revascularization within the treated vessel. Stent thrombosis was defined as an acute coronary syndrome with angiographic documentation of either vessel occlusion or thrombus within or adjacent to a previously successfully implanted stent, or in the absence of angiographic confirmation, either acute MI in the distribution of the treated vessel or death not clearly attributable to other causes. Stent thrombosis was categorized, according to the timing of the event, into: early (&#x02264; 1 month after the procedure) and late (1 month to 1 year after the procedure).</p><p>Plasma level of creatinine, CK-MB and troponin I was monitored before, immediately after and at 8 h and 24 h post-PCI. All patients were contacted by telephone or seen at a clinic review every month.</p></sec><sec><title>Quantitative angiographic analysis (QCA) and angiographic follow-up</title><p>Angiographic follow-up was scheduled at 8 months after the procedure unless clinically indicated earlier. QCA was performed at the Nanjing Heart Centre core laboratory (Nanjing, China) by observers who were blind to the treatment assignment. A validated computer-based edge detection system (CAAS II 4&#x000b7;1&#x000b7;1, Pie Medical Imaging, The Netherlands) was used to analyse QCA. Views were matched pre-procedural, post-procedural and at 8 month follow-up.</p><p>Vessels involved in the bifurcation lesion were divided into 3 segments: pre-bifurcation segment of main vessel (Proximal-MV), post-bifurcation segment of main vessel (Distal-MV), and side branch. Proximal-MV segment included the stented segment and 5 mm proximal to the stented segment. Distal-MV and side branch segments included the stented segment and 5 mm distal to the stent segment. Bifurcation angle was defined as the angle between the axis of the post-bifurcation segments of the main vessel and the side branch origin.</p><p>Angiographic success was defined as a residual stenosis &#x0003c; 30% with Thrombolysis in Myocardial Infarction (TIMI) flow 3 in both branches. Procedural success was defined as angiographic success in the absence of any in-hospital MACE. The final kissing balloon inflation was classified as &#x02018;satisfied&#x02019; (no waist at the side branch ostium) or &#x02018;unsatisfied&#x02019; (&#x02265; 20% diameter stenosis waist at the side branch ostium).</p></sec><sec><title>Statistics and data management</title><p>We assumed a cumulative incidence of 8-month MACE in classical crush cohorts of 25% and predicted that MACE in the DK crush group would be &#x02264; 12%. Therefore, 129 patients would be needed in each group with &#x0003e; 80% power using two-sided Fisher's exact test. Because of the uncertainty of follow-up, the sample size was expanded by 20%; therefore, a total of 312 patients were needed.</p><p>Continuous variables are expressed as mean &#x000b1; 1SD and compared using P-P plot and <sc>anova</sc> test. Categorical variables (as frequencies or percentages) were compared with chi-square statistics or Fisher's exact test. The primary end points were analysed by the Kaplan&#x02013;Meier method and log-rank test. Cox regression models were used to identify the predictors of TLR at 8 months. A <italic>P</italic>-value of &#x0003c; 0&#x000b7;05 was considered statistically significant. All data were analysed with SPSS version 11&#x000b7;5 (SPSS Inc., Chicago, IL).</p><p>Because of the previously reported importance of final kissing balloon inflations on long term success of bifurcation intervention, we also analysed patients with-, versus without-, final kissing balloon inflations.</p></sec></sec><sec><title>Results</title><sec><title>Baseline characteristics</title><p>A total of 311patients with 324 bifurcation lesions (156 patients with 163 lesions in the classical crush group, and 155 patients with 161 lesions in the DK crush group) were enrolled into this study, one patient in the classical crush group was excluded because of implantation of a bare-metal stent.</p><p>The two groups were matched regarding baseline clinical characteristics with the exception of diabetes mellitus (<xref ref-type="table" rid="tbl1">Table 1</xref>); more patients with diabetes were randomized to DK crush than classical crush (<italic>P</italic> = 0&#x000b7;03). Patients were admitted mainly due to unstable symptoms.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Baseline Clinical Characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Classical Crush</th><th align="center" rowspan="1" colspan="1">DK crush</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Overall Classical vs. DK Crush</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Without final kissing balloon</th><th align="center" rowspan="1" colspan="1">With final kissing balloon</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of patients (n)</td><td align="center" rowspan="1" colspan="1">156</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">155</td><td align="center" rowspan="1" colspan="1">&#x0003e; 1&#x000b7;0</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">63&#x000b7;9 &#x000b1; 8&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">64&#x000b7;1 &#x000b1; 7&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">63&#x000b7;7 &#x000b1; 8&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">63&#x000b7;8 &#x000b1; 9&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">Males (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">70&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">67&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">73&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">76&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">76&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">77&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">76&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">76&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;0</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperlipidaemia (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">62&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">60&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">68&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">68&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">8&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">12&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">27&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;03</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">62&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">58&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">64&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">63&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous PCI (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">11&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">9&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">11&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">11&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous MI (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">12&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">14&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">8&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">Unstable angina (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">70&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">67&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">71&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">69&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;0</td></tr><tr><td align="left" rowspan="1" colspan="1">Acute MI (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">16&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">19&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">15&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">15&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">62&#x000b7;7 &#x000b1; 13&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">61&#x000b7;0 &#x000b1; 9&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">64&#x000b7;2 &#x000b1; 5&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">61&#x000b7;6 &#x000b1; 11&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: LVEF, left ventricular ejection fraction; MI, myocardial infarction, PCI, percutaneous coronary intervention, DK, double kissing.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Lesions and procedural characteristics</title><p>Bifurcation lesions most commonly involved left anterior descending (LAD) and diagonal (<xref ref-type="table" rid="tbl2">Table 2</xref>). Final kissing balloon inflations were performed in 76% of the classical stent crush group and in 100% of the DK crush group (<italic>P</italic> &#x0003c; 0&#x000b7;001, <xref ref-type="table" rid="tbl1">Table 1</xref> and <xref ref-type="table" rid="tbl2">Table 2</xref>). Patients in the classical crush group who did not have final kissing balloon inflations had several typical features: smaller bifurcation angle, shorter lesions, shorter stent length in the main vessel, fewer distal left main trunk lesions, more left circumflex-obtuse marginal lesions, and shorter stent length and smaller stent diameter in the side branch. Independent factors for final kissing balloon inflation were lesion location (OR = 0&#x000b7;58, 95% CI 0&#x000b7;36&#x02013;0&#x000b7;92, <italic>P</italic> = 0&#x000b7;020), main vessel stent length (OR = 1&#x000b7;08, 95% CI 1&#x000b7;02&#x02013;1&#x000b7;14, <italic>P</italic> = 0&#x000b7;012), post-PCI side branch minimum lumen diameter (OR = 6&#x000b7;97, 95% CI 1&#x000b7;07&#x02013;45&#x000b7;78, <italic>P</italic> = 0&#x000b7;003), and bifurcation angle (OR = 1&#x000b7;02, 95% CI 1&#x000b7;00&#x02013;1&#x000b7;04, <italic>P</italic> = 0&#x000b7;043).</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Baseline lesion and procedural characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" colspan="3" rowspan="1">Classical crush</th><th align="center" rowspan="1" colspan="1">DK crush</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Overall classical vs. DK crush</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Without final kissing balloon</th><th align="center" rowspan="1" colspan="1">With final kissing balloon</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of lesions</td><td align="left" rowspan="1" colspan="1">163</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">124</td><td align="left" rowspan="1" colspan="1">161</td><td align="left" rowspan="1" colspan="1">&#x0003e; 1&#x000b7;0</td></tr><tr><td align="left" colspan="6" rowspan="1">Lesion characteristics</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Thrombus</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Severe calcification</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Tortuous</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">14</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Restenotic</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Chronic occlusion</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td align="left" colspan="6" rowspan="1">Lesion location (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LAD-diagonal</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">61&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">61&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">61&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">65&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Distal LM</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">15&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">21&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">15&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LCX-marginal</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">14&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">22&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">10&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">11&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Distal RCA</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">8&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">12&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">Angle (&#x000b0;)</td><td align="left" rowspan="1" colspan="1">52&#x000b7;8 &#x000b1; 23&#x000b7;0</td><td align="left" rowspan="1" colspan="1">46&#x000b7;2 &#x000b1; 13&#x000b7;9</td><td align="left" rowspan="1" colspan="1">55&#x000b7;6 &#x000b1; 25&#x000b7;4</td><td align="left" rowspan="1" colspan="1">53&#x000b7;8 &#x000b1; 22&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1">Guiding catheter (Fr)</td><td align="left" rowspan="1" colspan="1">7&#x000b7;1 &#x000b1; 0&#x000b7;5</td><td align="left" rowspan="1" colspan="1">7&#x000b7;2 &#x000b1; 0&#x000b7;4</td><td align="left" rowspan="1" colspan="1">7&#x000b7;1 &#x000b1; 0&#x000b7;3</td><td align="left" rowspan="1" colspan="1">6&#x000b7;5 &#x000b1; 0&#x000b7;5</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0&#x000b7;001</td></tr><tr><td align="left" rowspan="1" colspan="1">GP IIb/IIIa use (#)</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">13</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1">Balloons (#)</td><td align="left" rowspan="1" colspan="1">2&#x000b7;2 &#x000b1; 0&#x000b7;8</td><td align="left" rowspan="1" colspan="1">2&#x000b7;1 &#x000b1; 0&#x000b7;7</td><td align="left" rowspan="1" colspan="1">2&#x000b7;2 &#x000b1; 0&#x000b7;9</td><td align="left" rowspan="1" colspan="1">2&#x000b7;5 &#x000b1; 0&#x000b7;7</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0&#x000b7;01</td></tr><tr><td align="left" rowspan="1" colspan="1">Contrast volume (ml)</td><td align="left" rowspan="1" colspan="1">108&#x000b7;4 &#x000b1; 71&#x000b7;5</td><td align="left" rowspan="1" colspan="1">87&#x000b7;9 &#x000b1; 59&#x000b7;8</td><td align="left" rowspan="1" colspan="1">117&#x000b7;1 &#x000b1; 74&#x000b7;6</td><td align="left" rowspan="1" colspan="1">130&#x000b7;3 &#x000b1; 78&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;04</td></tr><tr><td align="left" rowspan="1" colspan="1">Procedure time (min)</td><td align="left" rowspan="1" colspan="1">34&#x000b7;9 &#x000b1; 18&#x000b7;4</td><td align="left" rowspan="1" colspan="1">34&#x000b7;9 &#x000b1; 18&#x000b7;3</td><td align="left" rowspan="1" colspan="1">33&#x000b7;9 &#x000b1; 18&#x000b7;5</td><td align="left" rowspan="1" colspan="1">46&#x000b7;5 &#x000b1; 24&#x000b7;2</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0&#x000b7;001</td></tr><tr><td align="left" rowspan="1" colspan="1">Cypher stents (%)</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">20</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;11</td></tr><tr><td align="left" colspan="6" rowspan="1">No of stents</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Main vessel</td><td align="left" rowspan="1" colspan="1">1&#x000b7;1 &#x000b1; 0&#x000b7;4</td><td align="left" rowspan="1" colspan="1">1&#x000b7;0 &#x000b1; 0&#x000b7;2</td><td align="left" rowspan="1" colspan="1">1&#x000b7;2 &#x000b1; 0&#x000b7;4</td><td align="left" rowspan="1" colspan="1">1&#x000b7;2 &#x000b1; 0&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Side branch</td><td align="left" rowspan="1" colspan="1">1&#x000b7;2 &#x000b1; 0&#x000b7;4</td><td align="left" rowspan="1" colspan="1">1&#x000b7;0 &#x000b1; 0&#x000b7;2</td><td align="left" rowspan="1" colspan="1">1&#x000b7;1 &#x000b1; 0&#x000b7;3</td><td align="left" rowspan="1" colspan="1">1&#x000b7;0 &#x000b1; 0&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;06</td></tr><tr><td align="left" colspan="6" rowspan="1">Overlapping stents (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Main vessel</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">10&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">13&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">17&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;14</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Side branch</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;7</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" colspan="6" rowspan="1">Max pressure (atm)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Main vessel</td><td align="left" rowspan="1" colspan="1">16&#x000b7;9 &#x000b1; 2&#x000b7;8</td><td align="left" rowspan="1" colspan="1">17&#x000b7;0 &#x000b1; 2&#x000b7;7</td><td align="left" rowspan="1" colspan="1">17&#x000b7;0 &#x000b1; 2&#x000b7;8</td><td align="left" rowspan="1" colspan="1">16&#x000b7;7 &#x000b1; 2&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Side branch</td><td align="left" rowspan="1" colspan="1">16&#x000b7;0 &#x000b1; 2&#x000b7;7</td><td align="left" rowspan="1" colspan="1">15&#x000b7;9 &#x000b1; 2&#x000b7;7</td><td align="left" rowspan="1" colspan="1">16&#x000b7;0 &#x000b1; 2&#x000b7;7</td><td align="left" rowspan="1" colspan="1">16&#x000b7;0 &#x000b1; 2&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" colspan="6" rowspan="1">Lesion length (mm)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Main vessel</td><td align="left" rowspan="1" colspan="1">20&#x000b7;0 &#x000b1; 9&#x000b7;7</td><td align="left" rowspan="1" colspan="1">16&#x000b7;7 &#x000b1; 5&#x000b7;5</td><td align="left" rowspan="1" colspan="1">21&#x000b7;4 &#x000b1; 10&#x000b7;7</td><td align="left" rowspan="1" colspan="1">21&#x000b7;3 &#x000b1; 11&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Side branch</td><td align="left" rowspan="1" colspan="1">10&#x000b7;5 &#x000b1; 7&#x000b7;5</td><td align="left" rowspan="1" colspan="1">10&#x000b7;2 &#x000b1; 7&#x000b7;6</td><td align="left" rowspan="1" colspan="1">10&#x000b7;6 &#x000b1; 7&#x000b7;5</td><td align="left" rowspan="1" colspan="1">10&#x000b7;3 &#x000b1; 6&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" colspan="6" rowspan="1">Stent length (mm)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Main vessel</td><td align="left" rowspan="1" colspan="1">25&#x000b7;0 &#x000b1; 12&#x000b7;7</td><td align="left" rowspan="1" colspan="1">28&#x000b7;1 &#x000b1; 5&#x000b7;4</td><td align="left" rowspan="1" colspan="1">22&#x000b7;0 &#x000b1; 14&#x000b7;3</td><td align="left" rowspan="1" colspan="1">22&#x000b7;2 &#x000b1; 12&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Side branch</td><td align="left" rowspan="1" colspan="1">17&#x000b7;9 &#x000b1; 7&#x000b7;0</td><td align="left" rowspan="1" colspan="1">15&#x000b7;4 &#x000b1; 3&#x000b7;1</td><td align="left" rowspan="1" colspan="1">18&#x000b7;8 &#x000b1; 8&#x000b7;0</td><td align="left" rowspan="1" colspan="1">17&#x000b7;4 &#x000b1; 5&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" colspan="6" rowspan="1">Stent diameter (mm)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Main vessel</td><td align="left" rowspan="1" colspan="1">3&#x000b7;39 &#x000b1; 0&#x000b7;54</td><td align="left" rowspan="1" colspan="1">3&#x000b7;37 &#x000b1; 0&#x000b7;55</td><td align="left" rowspan="1" colspan="1">3&#x000b7;42 &#x000b1; 0&#x000b7;54</td><td align="left" rowspan="1" colspan="1">3&#x000b7;44 &#x000b1; 0&#x000b7;35</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Side branch</td><td align="left" rowspan="1" colspan="1">2&#x000b7;78 &#x000b1; 0&#x000b7;39</td><td align="left" rowspan="1" colspan="1">2&#x000b7;59 &#x000b1; 0&#x000b7;33</td><td align="left" rowspan="1" colspan="1">2&#x000b7;84 &#x000b1; 0&#x000b7;39</td><td align="left" rowspan="1" colspan="1">2&#x000b7;71 &#x000b1; 0&#x000b7;44</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;2</td></tr><tr><td align="left" rowspan="1" colspan="1">Unsatisfactory final kissing balloon inflation (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="char" char="&#x000b7;" rowspan="1" colspan="1">27&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;3</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0&#x000b7;01</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; GP, glycoprotein; DK, double kissing.</p></fn></table-wrap-foot></table-wrap><p>The DK crush procedure was characterized by more contrast use (<italic>P</italic> = 0&#x000b7;04), more balloons (<italic>P</italic> &#x0003c; 0&#x000b7;01), longer procedural times (<italic>P</italic> &#x0003c; 0&#x000b7;001), and a lower rate of unsatisfactory final kissing balloon inflations (27&#x000b7;63% vs. 6&#x000b7;3%, <italic>P</italic> &#x0003c; 0&#x000b7;01).</p></sec><sec><title>QCA analysis</title><p>QCA analysis of the Proximal-MV segment is shown in <xref ref-type="table" rid="tbl3">Table 3</xref>. There were no significant differences between the two groups (classical vs. DK crush) pre-PCI or immediately post-PCI. However, at follow-up, late lumen loss was significantly greater and minimum lumen diameter was significantly smaller in the classical crush group. This difference was primarily attributable to the patients in the classical crush group who did not have final kissing balloon inflations and in whom restenosis in the body of the Proximal-MV stented segment was the most common pattern.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Quantative angiographic analysis of the pre-bifurcation main vessel (Proximal-MV) segment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">Classical crush</th><th align="center" rowspan="1" colspan="1">DK crush</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Overall classical vs. DK crush</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Without final kissing balloon</th><th align="center" rowspan="1" colspan="1">With final kissing balloon</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of lesions</td><td align="left" rowspan="1" colspan="1">135</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">105</td><td align="left" rowspan="1" colspan="1">130</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" colspan="6" rowspan="1">Baseline</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RVD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;86 &#x000b1; 0&#x000b7;63</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;87 &#x000b1; 0&#x000b7;62</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;84 &#x000b1; 0&#x000b7;58</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;85 &#x000b1; 0&#x000b7;53</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MLD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;94 &#x000b1; 0&#x000b7;57</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;96 &#x000b1; 0&#x000b7;56</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;92 &#x000b1; 0&#x000b7;49</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;93 &#x000b1; 0&#x000b7;49</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;16</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DS (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">64&#x000b7;5 &#x000b1; 13&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">65&#x000b7;9 &#x000b1; 14&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">63&#x000b7;7 &#x000b1; 14&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">64&#x000b7;8 &#x000b1; 13&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;13</td></tr><tr><td align="left" colspan="6" rowspan="1">Post-PCI</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RVD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;44 &#x000b1; 0&#x000b7;54</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;26 &#x000b1; 0&#x000b7;56</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;48 &#x000b1; 0&#x000b7;45</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;48 &#x000b1; 0&#x000b7;51</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MLD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;94 &#x000b1; 0&#x000b7;55</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;81 &#x000b1; 0&#x000b7;59</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;98 &#x000b1; 0&#x000b7;46</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;02 &#x000b1; 0&#x000b7;52</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DS (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">12&#x000b7;8 &#x000b1; 7&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">12&#x000b7;0 &#x000b1; 6&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">13&#x000b7;1 &#x000b1; 7&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">14&#x000b7;6 &#x000b1; 8&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Acute gain (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;88 &#x000b1; 0&#x000b7;58</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;80 &#x000b1; 0&#x000b7;59</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;91 &#x000b1; 0&#x000b7;55</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;96 &#x000b1; 0&#x000b7;56</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" colspan="6" rowspan="1">8-month follow-up</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RVD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;38 &#x000b1; 0&#x000b7;63</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;30 &#x000b1; 0&#x000b7;71</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;38 &#x000b1; 0&#x000b7;59</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;38 &#x000b1; 0&#x000b7;54</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MLD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;58 &#x000b1; 0&#x000b7;76</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;59 &#x000b1; 0&#x000b7;81<xref ref-type="table-fn" rid="tf3-1">*</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;72 &#x000b1; 0&#x000b7;85</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;89 &#x000b1; 0&#x000b7;86</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DS (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">22&#x000b7;6 &#x000b1; 24&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">25&#x000b7;4 &#x000b1; 21&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18&#x000b7;7 &#x000b1; 15&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">19&#x000b7;6 &#x000b1; 16&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late loss (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;38 &#x000b1; 0&#x000b7;12</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;42 &#x000b1; 0&#x000b7;15<xref ref-type="table-fn" rid="tf3-1">*</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;35 &#x000b1; 0&#x000b7;11</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;32 &#x000b1; 0&#x000b7;15</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;05</td></tr><tr><td align="left" colspan="6" rowspan="1">Restenosis (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Overall</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">8&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Edge</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;In-stent</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">13&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: RVD, reference vessel diameter; MLD, minimum lumen diameter; DS, diameter stenosis; DK, double kissing.</p></fn><fn id="tf3-1"><label>*</label><p><italic>P</italic> &#x0003c; 0&#x000b7;05 comparing classical crush without final kissing inflations to both classical crush with final kissing inflations as well as DK crush.</p></fn></table-wrap-foot></table-wrap><p>Analysis of the Distal-MV segment is shown in <xref ref-type="table" rid="tbl4">Table 4</xref>. There were no significant differences between the two groups (classical vs. DK crush).</p><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><p>Quantitative angiographic analysis of the post-bifurcation main vessel (Distal-MV) segment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">Classical crush</th><th align="center" rowspan="1" colspan="1">DK crush</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Overall classical vs. DK crush</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Without final kissing balloon</th><th align="center" rowspan="1" colspan="1">With final kissing balloon</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of lesions</td><td align="left" rowspan="1" colspan="1">135</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">105</td><td align="left" rowspan="1" colspan="1">130</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Baseline</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RVD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;56 &#x000b1; 0&#x000b7;49</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;57 &#x000b1; 0&#x000b7;46</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;51 &#x000b1; 0&#x000b7;42</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;53 &#x000b1; 0&#x000b7;41</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MLD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;62 &#x000b1; 0&#x000b7;25</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;65 &#x000b1; 0&#x000b7;22</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;62 &#x000b1; 0&#x000b7;23</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;65 &#x000b1; 0&#x000b7;25</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DS (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">62&#x000b7;1 &#x000b1; 11&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">64&#x000b7;3 &#x000b1; 13&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">61&#x000b7;7 &#x000b1; 18&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">65&#x000b7;6 &#x000b1; 19&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td align="left" colspan="6" rowspan="1">Post-PCI</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RVD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;15 &#x000b1; 0&#x000b7;57</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;24 &#x000b1; 0&#x000b7;59</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;23 &#x000b1; 0&#x000b7;55</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;26 &#x000b1; 0&#x000b7;55</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MLD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;67 &#x000b1; 0&#x000b7;56</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;69 &#x000b1; 0&#x000b7;60</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;67 &#x000b1; 0&#x000b7;54</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;96 &#x000b1; 0&#x000b7;57</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DS (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">14&#x000b7;3 &#x000b1; 6&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">14&#x000b7;7 &#x000b1; 5&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">13&#x000b7;1 &#x000b1; 4&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">13&#x000b7;5 &#x000b1; 5&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;11</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Acute gain (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;55 &#x000b1; 0&#x000b7;42</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;43 &#x000b1; 0&#x000b7;44</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;56 &#x000b1; 0&#x000b7;47</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;58 &#x000b1; 0&#x000b7;46</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" colspan="6" rowspan="1">8-month follow-up</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RVD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;98 &#x000b1; 0&#x000b7;46</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;89 &#x000b1; 0&#x000b7;43</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;02 &#x000b1; 0&#x000b7;45</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;92 &#x000b1; 0&#x000b7;47</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MLD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;46 &#x000b1; 0&#x000b7;47</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;47 &#x000b1; 0&#x000b7;44</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;41 &#x000b1; 0&#x000b7;39</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;48 &#x000b1; 0&#x000b7;36</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DS (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">23&#x000b7;8 &#x000b1; 19&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">24&#x000b7;3 &#x000b1; 21&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">19&#x000b7;6 &#x000b1; 17&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18&#x000b7;5 &#x000b1; 16&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late loss (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;36 &#x000b1; 0&#x000b7;11</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;34 &#x000b1; 0&#x000b7;16</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;33 &#x000b1; 0&#x000b7;13</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;31 &#x000b1; 0&#x000b7;11</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td align="left" colspan="6" rowspan="1">Restenosis (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Overall</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">10&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Edge</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;In-stent</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: RVD, reference vessel diameter; MLD, minimum lumen diameter; DS, diameter stenosis; DK, double kissing.</p></fn></table-wrap-foot></table-wrap><p>Analysis of the side branch is shown in <xref ref-type="table" rid="tbl5">Table 5</xref>. Smaller acute gain and greater final diameter stenosis were found in the classical crush vs. the DK crush branches primarily due to differences in lesions not undergoing final kissing balloon inflations. At follow-up late loss was greater, minimal lumen diameter (MLD) was smaller, final diameter stenosis was also greater, and restenosis was more common in the classical crush group compared to the DK crush group again, primarily due to the difference in lesions not undergoing final kissing balloon inflations. The ostial side branch was the common site of the MLD both post-PCI and at 8 month follow-up in lesions treated with the classical crush technique, but without final kissing balloon inflations; the restenosis rate at this site was 33&#x000b7;3%.</p><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><p>Quantitative angiographic analysis of the side branch</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">Classical crush</th><th align="center" rowspan="1" colspan="1">DK crush</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Overall classical vs. DK crush</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Without final kissing balloon</th><th align="center" rowspan="1" colspan="1">With final kissing balloon</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of lesions</td><td align="left" rowspan="1" colspan="1">135</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">105</td><td align="left" rowspan="1" colspan="1">130</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Baseline</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RVD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;45 &#x000b1; 0&#x000b7;45</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;45 &#x000b1; 0&#x000b7;33</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;49 &#x000b1; 0&#x000b7;48</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;46 &#x000b1; 0&#x000b7;54</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MLD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;84 &#x000b1; 0&#x000b7;51</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;83 &#x000b1; 0&#x000b7;55</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;85 &#x000b1; 0&#x000b7;59</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;84 &#x000b1; 0&#x000b7;58</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DS (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">65&#x000b7;7 &#x000b1; 18&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">62&#x000b7;4 &#x000b1; 17&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">66&#x000b7;3 &#x000b1; 19&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">65&#x000b7;4 &#x000b1; 19&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td align="left" colspan="6" rowspan="1">Post-PCI</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RVD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;85 &#x000b1; 0&#x000b7;39</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;85 &#x000b1; 0&#x000b7;36</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;86 &#x000b1; 0&#x000b7;39</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;88 &#x000b1; 0&#x000b7;40</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;13</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MLD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;56 &#x000b1; 0&#x000b7;42</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;18 &#x000b1; 0&#x000b7;46</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;59 &#x000b1; 0&#x000b7;49</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;59 &#x000b1; 0&#x000b7;45</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DS (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">19&#x000b7;4 &#x000b1; 8&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">22&#x000b7;6 &#x000b1; 9&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">15&#x000b7;5 &#x000b1; 9&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">14&#x000b7;6 &#x000b1; 8&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;04</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Acute gain (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;45 &#x000b1; 0&#x000b7;59</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;37 &#x000b1; 0&#x000b7;57<xref ref-type="table-fn" rid="tf5-1">*</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;64 &#x000b1; 0&#x000b7;55</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;69 &#x000b1; 0&#x000b7;64</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;01</td></tr><tr><td align="left" colspan="6" rowspan="1">8-month follow-up</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RVD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;81 &#x000b1; 0&#x000b7;41</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;80 &#x000b1; 0&#x000b7;37</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;83 &#x000b1; 0&#x000b7;42</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;82 &#x000b1; 0&#x000b7;54</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MLD (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;95 &#x000b1; 0&#x000b7;45</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;52 &#x000b1; 0&#x000b7;50<xref ref-type="table-fn" rid="tf5-1">*</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;24 &#x000b1; 0&#x000b7;52</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;29 &#x000b1; 0&#x000b7;71</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DS (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">38&#x000b7;6 &#x000b1; 17&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">39&#x000b7;4 &#x000b1; 17&#x000b7;7<xref ref-type="table-fn" rid="tf5-1">*</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">23&#x000b7;9 &#x000b1; 14&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">21&#x000b7;2 &#x000b1; 14&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;03</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Late loss (mm)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;48 &#x000b1; 0&#x000b7;28</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;51 &#x000b1; 0&#x000b7;39<xref ref-type="table-fn" rid="tf5-1">*</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;34 &#x000b1; 0&#x000b7;23</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;33 &#x000b1; 0&#x000b7;25</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;04</td></tr><tr><td align="left" colspan="6" rowspan="1">Restenosis (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Overall</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">24&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">36&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20&#x000b7;9<xref ref-type="table-fn" rid="tf5-2">**</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">12&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Edge<xref ref-type="table-fn" rid="tf5-3">&#x02020;</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">17&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">33&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">13&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;01</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;In-stent</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;08</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: RVD, reference vessel diameter; MLD, minimum lumen diameter; DS, diameter stenosis; DK, double kissing.</p></fn><fn id="tf5-1"><label>*</label><p><italic>P</italic> &#x0003c; 0&#x000b7;001 comparing classical crush without final kissing inflations to both classical crush with final kissing inflations as well as DK crush.</p></fn><fn id="tf5-2"><label>**</label><p><italic>P</italic> = 0&#x000b7;01 comparing classical crush with final kissing inflations to DK crush.</p></fn><fn id="tf5-3"><label>&#x02020;</label><p>indicates the restenosis at ostial side branch (within 5 mm proximal to side stent).</p></fn></table-wrap-foot></table-wrap><p>Comparison of restenosis rate is shown in <xref ref-type="fig" rid="fig01">Fig. 1</xref>. The overall restenosis rate (defined by any one of 3 segments analysed having restenosis) was 32&#x000b7;3% in classical crush and 20&#x000b7;3% in the DK crush groups (<italic>P</italic> = 0&#x000b7;01). This difference was mainly attributable to patients in the classical crush group who did not undergo final kissing inflation.</p><fig id="fig01" position="float"><label>Figure 1</label><caption><p>The comparison of restenosis rate at 3 segments between two groups: classical crush vs. double kissing (DK) crush. Overall, as indicated, any one of 3 analysed segments had restenosis. Proximal-MV, pre-bifurcation segment of main vessel; Distal-MV, post-bifurcation segment of main vessel; MV, both pre- and post-bifurcation segments of main vessel; SB, side branch; With FKBI, with final kissing balloon inflation; Without FKBI, without final kissing balloon inflation.</p></caption><graphic xlink:href="eci0038-0361-f1"/></fig></sec><sec><title>Clinical outcomes</title><p>Clinical results are shown in <xref ref-type="table" rid="tbl6">Table 6</xref>. Procedural success was 91&#x000b7;1% in the classical crush group (87&#x000b7;2% in classical crush without final kissing balloon inflations and 92&#x000b7;3% in classical crush with final kissing balloon inflations); it was 96&#x000b7;1% in DK crush. Although there was one intraprocedural stent thrombosis in the DK crush group, there was no difference in in-hospital MACE between treated groups.</p><table-wrap id="tbl6" position="float"><label>Table 6</label><caption><p>Major adverse cardiac events</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">Classical crush</th><th align="center" rowspan="1" colspan="1">DK crush</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> Overall classical vs. DK crush</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Overall</th><th align="center" rowspan="1" colspan="1">Without final kissing balloon</th><th align="center" rowspan="1" colspan="1">With final kissing balloon</th><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of lesions</td><td align="left" rowspan="1" colspan="1">156</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">117</td><td align="left" rowspan="1" colspan="1">155</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Angiographic success (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">97&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">94&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">98&#x000b7;3</td><td align="left" rowspan="1" colspan="1">100</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">Procedural success (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">91&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">87&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">92&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">96&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;3</td></tr><tr><td align="left" rowspan="1" colspan="1">In hospital MACE (%)</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">6&#x000b7;4</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cardiac death</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Q wave MI</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Non-Q MI</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">7&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">4&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TLR</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;6</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TVR</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;6</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">Stent thrombosis</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;6</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td align="center" colspan="6" rowspan="1">8-month MACE (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cumulative</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">24&#x000b7;4</td><td align="left" rowspan="1" colspan="1">35&#x000b7;9<xref ref-type="table-fn" rid="tf6-1">*</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">19&#x000b7;7</td><td align="left" rowspan="1" colspan="1">11&#x000b7;4<xref ref-type="table-fn" rid="tf6-2">**</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;02</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cardiac death</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">2&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;6</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Q wave MI</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;5</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Non-Q MI</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">11&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">10&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">8&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">9&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TLR</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">18&#x000b7;9</td><td align="left" rowspan="1" colspan="1">22&#x000b7;6<xref ref-type="table-fn" rid="tf6-1">*</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">17&#x000b7;8</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">9&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;03</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TVR</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">21&#x000b7;9</td><td align="left" rowspan="1" colspan="1">26&#x000b7;5<xref ref-type="table-fn" rid="tf6-1">*</xref></td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">20&#x000b7;0</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">10&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">0&#x000b7;03</td></tr><tr><td align="left" rowspan="1" colspan="1">Stent thrombosis</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">3&#x000b7;2</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">5&#x000b7;1</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;7</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;3</td><td align="char" char="&#x000b7;" rowspan="1" colspan="1">1&#x000b7;0</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: MACE, major adverse cardiac events; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization; DK, double kissing.</p></fn><fn id="tf6-1"><label>*</label><p><italic>P</italic> &#x0003c; 0&#x000b7;01 comparing classical crush without final kissing inflations to both classical crush with final kissing inflations as well as DK crush.</p></fn><fn id="tf6-2"><label>**</label><p><italic>P</italic> &#x0003c; 0&#x000b7;05 comparing classical crush with final kissing inflations to DK crush.</p></fn></table-wrap-foot></table-wrap><p>Clinical follow-up was available in 100% of patients, and angiographic follow-up was available in 82% of patients (overall, 257 patients with 265 lesions) at a mean period of 246 &#x000b1; 17 days after procedure. Cumulative 8 month MACE was 24&#x000b7;4% in the classical crush group (35&#x000b7;9% in patients without final kissing balloon inflations and 19&#x000b7;7% in patients with final kissing balloon inflations), significantly greater than in the DK crush group (11&#x000b7;4%, <italic>P</italic> = 0&#x000b7;02, <xref ref-type="table" rid="tbl6">Table 6</xref>). This was primarily attributed to a much higher rate of revascularization in the classical crush treated bifurcation lesions that did not include final kissing balloon inflations. There was one death from acute inferior wall infarction 5 months after treatment of an LAD-diagonal lesion in the DK crush group. Two patients in the classical crush group (one with and one without final kissing balloon inflations) died from acute MI in the distribution of the treated vessels. The incidence of stent thrombosis was 3&#x000b7;2% in the classical crush group (5&#x000b7;1% in &#x02018;without&#x02019; and 1&#x000b7;7% in &#x02018;with&#x02019; final kissing balloon inflations) and 1&#x000b7;3% in the DK crush group. The TLR-free survival rate was 75&#x000b7;4% in the classical crush group (71&#x000b7;2% in &#x02018;without&#x02019; and 77&#x000b7;6% in &#x02018;with&#x02019; final kissing balloon inflations) vs. 89&#x000b7;5% in the DK crush group (<italic>P</italic> = 0&#x000b7;002, <xref ref-type="fig" rid="fig02">Figs 2</xref> and <xref ref-type="fig" rid="fig03">3</xref>).</p><fig id="fig02" position="float"><label>Figure 2</label><caption><p>Cumulative survival rate free from target lesion revascularization (TLR) at 8 month follow-up by Kaplan-Meier method. DK, double kissing.</p></caption><graphic xlink:href="eci0038-0361-f2"/></fig><fig id="fig03" position="float"><label>Figure 3</label><caption><p>Cumulative survival rate free from target lesion revascularization (TLR) at 8 month follow-up by Kaplan&#x02013;Meier method. With FKBI, with final kissing balloon inflation; Without FKBI, without final kissing balloon inflation.</p></caption><graphic xlink:href="eci0038-0361-f3"/></fig><p>Lack of final kissing balloon inflations was the only independent predictor of post-procedural stent thrombosis (OR = 1&#x000b7;60, 95% CI 1&#x000b7;63&#x02013;4&#x000b7;756, <italic>P</italic> = 0&#x000b7;035). By Cox regression analysis, side branch minimal lumen diameter (HR = 16&#x000b7;57, 95% CI 3&#x000b7;39&#x02013;11&#x000b7;20, <italic>P</italic> = 0&#x000b7;001) and lack of DK crush technique (HR 24&#x000b7;68, 95% CI 4&#x000b7;15&#x02013;23&#x000b7;55, <italic>P</italic> = 0&#x000b7;001) were two independent predictors of MACE. Independent predictors of TLR were an unsatisfactory final kissing balloon inflation (HR = 12&#x000b7;21, 95% CI 0&#x000b7;01&#x02013;0&#x000b7;34, <italic>P</italic> = 0&#x000b7;002) and lack of DK crush technique (HR = 16&#x000b7;05, 95% CI 1&#x000b7;01&#x02013;4&#x000b7;83, <italic>P</italic> = 0&#x000b7;001).</p></sec></sec><sec><title>Discussion</title><p>The DKCRUSH-1 study is the first large prospective, multicentre randomized trial to compare the two different crush stenting techniques in patients with coronary bifurcation lesions. Previous studies [<xref ref-type="bibr" rid="b11">11</xref>] suggested that the clinical outcome was similar between the single stent and the double stent groups in an international randomized trial for bifurcation lesions. The MACE at 6 months was very low but the restenosis rate (19&#x000b7;2%) of the side branch was still high when utilizing the single stent strategy. Hoye [<xref ref-type="bibr" rid="b12">12</xref>]<italic>et al</italic>. reported in their study of 231 patients after classical crush stent with a survival free TLR rate of 90&#x000b7;3%, survival free of MACE of 83&#x000b7;5%, possible stent thrombosis of 4&#x000b7;3%, and a restenosis rate of the side branch of 25&#x000b7;3% at 9 months. Another prospective registry by Moussa <italic>et al</italic>. [<xref ref-type="bibr" rid="b9">9</xref>] revealed that TLR at 6 months after classical crush stenting using sirolimus-eluting stents was 11&#x000b7;3% but FKBI was performed in 87&#x000b7;5% patients. The most effective strategy to treat bifurcation lesions is still unknown [<xref ref-type="bibr" rid="b13">13</xref>,<xref ref-type="bibr" rid="b14">14</xref>]. Our study showed a remarkable 100% FKBI rate, a stent thrombosis rate of 1&#x000b7;3%, side-branch restenosis rate of 12&#x000b7;3%, and a survival free TLR rate of 89&#x000b7;5% at 8 months in the DK crush group. Since this is a randomized study, superiority to the classical crush stent strategy is noted.</p><sec><title>Effect of randomization on results</title><p>Diabetic patients were at high risk for restenosis and MACE after PCI [<xref ref-type="bibr" rid="b15">15</xref>,<xref ref-type="bibr" rid="b16">16</xref>], and a predictor of TLR after the classical crush technique. [<xref ref-type="bibr" rid="b17">17</xref>] In the current study there was no sub-randomization of diabetic patients, and more diabetic patients were randomized to the DK crush than to the classical crush technique. This, if anything, minimized the effectiveness of the DK crush technique.</p><p>We previously reported that the DK crush technique was superior to classical crush regarding procedural time, balloons used and contrast volume [<xref ref-type="bibr" rid="b17">17</xref>]. However, these advantages were lost in this current randomized study. Of note, smaller guiding catheters were used in DK crush treated patients.</p></sec><sec><title>Mechanisms and importance of optimal final kissing balloon inflations</title><p>Previous studies have reported that FKBI were necessary to optimize clinical outcomes [<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref>,<xref ref-type="bibr" rid="b17">17</xref>]. One study reported that a narrow distal left main artery bifurcation angle was associated with less ostial left circumflex (LCX) stent expansion [<xref ref-type="bibr" rid="b18">18</xref>]. Dzavik <italic>et al</italic>. concluded that a bifurcation angle &#x02265; 50&#x000b0; was an independent predictor of MACE after classical crush [<xref ref-type="bibr" rid="b19">19</xref>]. Ormiston <italic>et al</italic>. demonstrated that a kissing balloon inflation did not achieve full expansion of the side branch stent with a bifurcation angle of 80&#x000b0;[<xref ref-type="bibr" rid="b20">20</xref>]. Conversely, in the current study the bifurcation angle in classical crush without final kissing balloon inflations was lower than that in the other two groups.</p><p>Distorted side stent geometry and irregularity in overlapped stent strut layers at the carina of bifurcation are two common geographic characteristics immediately after the classical crush technique. In addition to technical pitfalls i.e. the guide wire is commonly advanced under the side branch stent rather than into the true stent lumen, [<xref ref-type="bibr" rid="b10">10</xref>] less expanded side branch stents with irregular and small stent cells after classical crush do not allow for easy advancement of post-dilation balloons. Similar to the present study, previous studies demonstrate that the post-stent MLD is commonly seen at the ostial side branch [<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b21">21</xref>]. The main difference between classical and DK crush was the introduction of a first kissing balloon inflation prior to implanting the second stent. This suggests that the first kissing inflation not only repaired the distorted geometry, but also enlarged the cells of the side branch stent allowing easier performance of FKBI. The finding in the current study that left main bifurcation lesions had the highest rate of final kissing balloon inflations supports this concept.</p><p>We also found an influence of main vessel stent length and lesion site on FKBI. Explanations include [<xref ref-type="bibr" rid="b1">1</xref>] careless overlapping of two main vessel stents at the level of carina and [<xref ref-type="bibr" rid="b2">2</xref>] longer main vessel stents may be associated with stent-vessel wall malapposition, resulting in incorrect advancement of the guide wire [<xref ref-type="bibr" rid="b20">20</xref>,<xref ref-type="bibr" rid="b21">21</xref>]. From subgroup analysis, we found that the success of rate of final kissing inflation was lower when lesions were located at distal right coronary or LCX, compared to lesions involved LAD-D, or distal left main. However, this finding was not included in this manuscript (unpublished data).</p><p>Restenosis is highest at the side branch ostium after bifurcation stenting; however, its mechanism is not entirely known. Ge <italic>et al</italic>. proposed that polymer rupture and uneven distribution of stent struts were two possible factors contributing to this phenomenon [<xref ref-type="bibr" rid="b17">17</xref>]. Murasato <italic>et al</italic>. reported that final kissing balloon inflations improved the apposition of the stent to the vessel wall; however, the narrowed side branch stent at the overlapping site, and a metal mass limited the complete side branch balloon expansion resulting in severe stent strut malapposition [<xref ref-type="bibr" rid="b21">21</xref>,<xref ref-type="bibr" rid="b22">22</xref>].</p><p>Part of the reason that DK crush stenting can improve the clinical outcomes is by achieving a 100% final kissing balloon inflation and also reducing the unsatisfactory kissing. In the present study unsatisfactory kissing balloon inflation was an independent predictor of TLR. This appeared to have been alleviated by the initial kissing balloon inflation that is part of the DK procedure. Furthermore, unsatisfactory kissing balloon inflations not only affected the side branch ostium, but also increased the restenosis rate in Proximal-MV segment in this study. The mechanisms are yet unknown.</p><p>Pathological studies have suggested that bifurcation stenting is associated with increased DES thrombosis [<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b23">23</xref>&#x02013;<xref ref-type="bibr" rid="b25">25</xref>]. The cause of DES late stent thrombosis is multifactorial with delayed healing in combination with other clinical and procedural risk factors playing a role. In the current study the only independent predictor of stent thrombosis was the lack of final kissing balloon inflations suggesting that optimal final kissing balloon inflations have the potential to minimize the risks of stent thrombosis within the first year.</p></sec><sec><title>Clinical implications</title><p>The current observations have important clinical implications. With the introduction of the DK crush stenting technique, a paradigm shift occurs in the crush stenting strategy, displacing the classical crush stenting by the DK crush stenting when treating patients with bifurcation lesions. According to the present results, the DK crush stenting has reduced the unfavourable outcome, reducing clinical and angiographic restenosis rate. Percutaneous intervention with the use of the DK crush stenting technique seems to be the preferred strategy.</p></sec><sec><title>Limitations</title><p>The present study was a randomized one but it had an open study design. The operators were aware of the technique used. Operators' experience on procedure times, contrast volumes, balloons used, and how to control the quality of kissing balloon inflations may all have an effect to the outcomes. On the other hand, GP IIbIIIa and IVUS were not used routinely. The data on clinical outcome might be improved. In addition, this was only a randomized trial between the two different crush stents techniques; other strategies, e.g. SKS (simultaneous kissing stents), T stents, V-stents, Y-stents or Culotte stents, etc. were not studied. There is no information to address other stenting techniques.</p></sec></sec><sec><title>Conclusions</title><p>The DK crush technique for bifurcation DES stenting appears to improve outcome by allowing 100% FKBI and optimizing acute procedural results.</p></sec><sec><title>Address</title><p>Nanjing First Hospital of Nanjing Medical University, Nanjing, China (S. L. Chen, J. J. Zhang, F. Ye); Beijing Anzhen Hospital of Capital Medical University, Beijing, China (Y. D. Chen); Krishna Heart Institute, India (T. Patel); Tokushio Hospital, Osaka, Japan (K. Kawajiri); Queen Mary Hospital, Hong Kong, China (M. Lee); Beth Israel Hospital, New York, USA (T. W. Kwan); Cardiac Research Foundation, Columbia University, New York, USA (G. Mintz); National University Hospital, Singapore (H. C. Tan).</p></sec></body><back><ack><p>The authors wish to thank Dr T. Damras for his collaboration in this study and for his expertise in the Dk crush technique. We are also grateful to Dr Damras for reviewing this manuscript prior to submission to the journal.</p></ack><ref-list><title>References</title><ref id="b1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al Suwadi</surname><given-names>J</given-names></name><name><surname>Yeh</surname><given-names>W</given-names></name><name><surname>Cohen</surname><given-names>HA</given-names></name><name><surname>Detre</surname><given-names>KM</given-names></name><name><surname>Williams</surname><given-names>DO</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names><suffix>Jr</suffix></name></person-group><article-title>Immediate and one-year outcome in patients with coronary bifurcation lesions in the modern era (NHLBI dynamic registry)</article-title><source>Am J Cardiol</source><year>2001</year><volume>87</volume><fpage>1139</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">11356386</pub-id></citation></ref><ref id="b2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Moses</surname><given-names>JW</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Ludwig</surname><given-names>J</given-names></name><name><surname>Holmes</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Spanos</surname><given-names>V</given-names></name><etal/></person-group><article-title>Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions</article-title><source>Circulation</source><year>2004</year><volume>109</volume><fpage>1244</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">14981005</pub-id></citation></ref><ref id="b3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lefevre</surname><given-names>T</given-names></name><name><surname>Louvard</surname><given-names>Y</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name><name><surname>Dumas</surname><given-names>P</given-names></name><name><surname>Loubeyre</surname><given-names>C</given-names></name><name><surname>Benslimane</surname><given-names>A</given-names></name><etal/></person-group><article-title>Stenting of bifurcation lesions: classification, treatments and results</article-title><source>Catheter Cardiovasc Interv</source><year>2000</year><volume>49</volume><fpage>274</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">10700058</pub-id></citation></ref><ref id="b4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iakovou</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name></person-group><article-title>Contemporary stent treatment of coronary bifurcations</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>46</volume><fpage>1446</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">16226167</pub-id></citation></ref><ref id="b5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Louvard</surname><given-names>Y</given-names></name><name><surname>Lefevre</surname><given-names>T</given-names></name><name><surname>Morice</surname><given-names>MC</given-names></name></person-group><article-title>Percutaneous coronary intervention for bifurcation coronary disease</article-title><source>Heart</source><year>2004</year><volume>90</volume><fpage>713</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">15145893</pub-id></citation></ref><ref id="b6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Nishida</surname><given-names>T</given-names></name><name><surname>Adamian</surname><given-names>MG</given-names></name><name><surname>Briguori</surname><given-names>C</given-names></name><name><surname>Vaghetti</surname><given-names>M</given-names></name><name><surname>Corvaja</surname><given-names>N</given-names></name><etal/></person-group><article-title>Bifurcation lesions: two stents versus one stent: immediate and follow-up results</article-title><source>J Am Coll Cardiol</source><year>2000</year><volume>35</volume><fpage>1145</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">10758954</pub-id></citation></ref><ref id="b7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Stankovic</surname><given-names>G</given-names></name><name><surname>Orlic</surname><given-names>D</given-names></name><name><surname>Corvaja</surname><given-names>N</given-names></name><name><surname>Liistro</surname><given-names>F</given-names></name><name><surname>Airodi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Modified T-stenting technique with crushing for bifurcation lesions: immediate results and 30-day outcome</article-title><source>Catheter Cardiovasc Interv</source><year>2003</year><volume>60</volume><fpage>145</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">14517916</pub-id></citation></ref><ref id="b8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Iakovou</surname><given-names>I</given-names></name><name><surname>Cosgrave</surname><given-names>J</given-names></name><name><surname>Agostoni</surname><given-names>P</given-names></name><name><surname>Airoldi</surname><given-names>F</given-names></name><name><surname>Sangiorgi</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Treatment of bifurcation lesions with two stents: one year angiographic and clinical follow-up of crush versus T stenting</article-title><source>Heart</source><year>2006</year><volume>92</volume><fpage>371</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15964941</pub-id></citation></ref><ref id="b9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moussa</surname><given-names>I</given-names></name><name><surname>Costa</surname><given-names>RA</given-names></name><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Lansky</surname><given-names>AJ</given-names></name><name><surname>Lasic</surname><given-names>Z</given-names></name><name><surname>Cristea</surname><given-names>E</given-names></name><etal/></person-group><article-title>A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the &#x02018;crush technique&#x02019;</article-title><source>Am J Cardiol</source><year>2006</year><volume>97</volume><fpage>1317</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">16635603</pub-id></citation></ref><ref id="b10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SL</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>JJ</given-names></name><name><surname>Zhu</surname><given-names>ZS</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Shan</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>DK crush technique: Modified treatment of bifurcation lesions in coronary artery</article-title><source>Chinese Med J</source><year>2005</year><volume>118</volume><fpage>1746</fpage><lpage>50</lpage></citation></ref><ref id="b11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steigen</surname><given-names>TK</given-names></name><name><surname>Maeng</surname><given-names>M</given-names></name><name><surname>Wiseth</surname><given-names>R</given-names></name><name><surname>Erglis</surname><given-names>A</given-names></name><name><surname>Kumsars</surname><given-names>I</given-names></name><name><surname>Narbute</surname><given-names>I</given-names></name><etal/></person-group><collab>for the Nordic PCI Study Group</collab><article-title>Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: The Nordic bifurcation Study</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>1955</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17060387</pub-id></citation></ref><ref id="b12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoye</surname><given-names>A</given-names></name><name><surname>Iakovou</surname><given-names>I</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>van Mieghem</surname><given-names>CA</given-names></name><name><surname>Ong</surname><given-names>AT</given-names></name><name><surname>Cosqrave</surname><given-names>J</given-names></name><etal/></person-group><article-title>Long-term outcomes after stenting of bifurcation lesions with the &#x02018;crush&#x02019; technique: predictors of an adverse outcome</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>47</volume><fpage>1949</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">16697310</pub-id></citation></ref><ref id="b13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assali</surname><given-names>AR</given-names></name><name><surname>Assa</surname><given-names>HV</given-names></name><name><surname>Ben-Dor</surname><given-names>I</given-names></name><name><surname>Teplistky</surname><given-names>I</given-names></name><name><surname>Solodkv</surname><given-names>A</given-names></name><name><surname>Brosh</surname><given-names>D</given-names></name><etal/></person-group><article-title>Drug-eluting stents in bifurcation lesions: to stent one branch or both?</article-title><source>Catheter Cardiovasc Interv</source><year>2006</year><volume>68</volume><fpage>891</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17086532</pub-id></citation></ref><ref id="b14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melikian</surname><given-names>N</given-names></name><name><surname>Airoldi</surname><given-names>F</given-names></name><name><surname>Di Mario</surname><given-names>C</given-names></name></person-group><article-title>Coronary bifurcation stenting: current techniques, outcome and possible future developments</article-title><source>Minerva Cardioangiol</source><year>2004</year><volume>52</volume><fpage>365</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">15514572</pub-id></citation></ref><ref id="b15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastrati</surname><given-names>A</given-names></name><name><surname>Dibra</surname><given-names>A</given-names></name><name><surname>Eberle</surname><given-names>S</given-names></name><name><surname>Mehilli</surname><given-names>J</given-names></name><name><surname>Suarez de Lezo</surname><given-names>J</given-names></name><name><surname>Goy</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials</article-title><source>JAMA</source><year>2005</year><volume>294</volume><fpage>819</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">16106007</pub-id></citation></ref><ref id="b16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CW</given-names></name><name><surname>Park</surname><given-names>DW</given-names></name><name><surname>Lee</surname><given-names>BK</given-names></name><name><surname>Kim</surname><given-names>YH</given-names></name><name><surname>Hong</surname><given-names>MK</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries</article-title><source>Am J Cardiol</source><year>2006</year><volume>97</volume><fpage>506</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">16461047</pub-id></citation></ref><ref id="b17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Airoldi</surname><given-names>F</given-names></name><name><surname>Iakovou</surname><given-names>I</given-names></name><name><surname>Cosgrave</surname><given-names>J</given-names></name><name><surname>Michev</surname><given-names>I</given-names></name><name><surname>Sangiorgi</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>46</volume><fpage>613</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">16098424</pub-id></citation></ref><ref id="b18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murasato</surname><given-names>Y</given-names></name></person-group><article-title>Impact of three-dimensional characteristics of the left main coronary artery bifurcation on outcome of crush stenting</article-title><source>Catheter Cardiovasc Interv</source><year>2007</year><volume>69</volume><fpage>248</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">17211894</pub-id></citation></ref><ref id="b19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dzavik</surname><given-names>V</given-names></name><name><surname>Kharbanda</surname><given-names>R</given-names></name><name><surname>Ivanov</surname><given-names>J</given-names></name><name><surname>Ing</surname><given-names>DJ</given-names></name><name><surname>Bsc</surname><given-names>SB</given-names></name><name><surname>Mackie</surname><given-names>K</given-names></name><etal/></person-group><article-title>Predictors of long-term outcome after crush stenting of coronary bifurcation lesions: importance of the bifurcation angle</article-title><source>Am Heart J</source><year>2006</year><volume>152</volume><fpage>759</fpage><lpage>62</lpage></citation></ref><ref id="b20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ormiston</surname><given-names>JA</given-names></name><name><surname>Currie</surname><given-names>E</given-names></name><name><surname>Webster</surname><given-names>MW</given-names></name><name><surname>Kay</surname><given-names>P</given-names></name><name><surname>Ruygrok</surname><given-names>PN</given-names></name><name><surname>Stewart</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Drug-eluting stents for coronary bifurcations: insights into the crush technique</article-title><source>Catheter Cardiovasc Interv</source><year>2004</year><volume>63</volume><fpage>332</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15505853</pub-id></citation></ref><ref id="b21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>R</given-names></name><name><surname>Mintz</surname><given-names>G</given-names></name><name><surname>Carlier</surname><given-names>SG</given-names></name><name><surname>Lansky</surname><given-names>AJ</given-names></name><name><surname>Mousa</surname><given-names>I</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><etal/></person-group><article-title>Bifurcation coronary lesions treated with the &#x02018;crush&#x02019; technique: an intravascular ultrasound analysis</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>46</volume><fpage>599</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">16098422</pub-id></citation></ref><ref id="b22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murasato</surname><given-names>Y</given-names></name><name><surname>Suzuka</surname><given-names>H</given-names></name><name><surname>Kamezaki</surname><given-names>F</given-names></name></person-group><article-title>Vascular endoscopic and macroscopic observations after crush stenting of coronary artery bifurcations in pigs</article-title><source>Catheter Cardiovasc Interv</source><year>2005</year><volume>66</volume><fpage>237</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16152654</pub-id></citation></ref><ref id="b23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>AV</given-names></name><name><surname>Joner</surname><given-names>M</given-names></name><name><surname>Nakazawa</surname><given-names>G</given-names></name><name><surname>Kolodgie</surname><given-names>F</given-names></name><name><surname>Newell</surname><given-names>J</given-names></name><name><surname>John</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization</article-title><source>Circulation</source><year>2007</year><volume>115</volume><fpage>2435</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17438147</pub-id></citation></ref><ref id="b24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joner</surname><given-names>M</given-names></name><name><surname>Finn</surname><given-names>AV</given-names></name><name><surname>Farb</surname><given-names>A</given-names></name><name><surname>Mont</surname><given-names>EK</given-names></name><name><surname>Kolodgie</surname><given-names>FD</given-names></name><name><surname>Ladich</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><fpage>203</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16814668</pub-id></citation></ref><ref id="b25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iakovou</surname><given-names>I</given-names></name><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Bonizzoni</surname><given-names>E</given-names></name><name><surname>Ge</surname><given-names>L</given-names></name><name><surname>Sangiorgi</surname><given-names>GM</given-names></name><name><surname>Stankovic</surname><given-names>G</given-names></name><etal/></person-group><article-title>Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents</article-title><source>JAMA</source><year>2005</year><volume>4</volume><fpage>2126</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">15870416</pub-id></citation></ref></ref-list></back></article>





